Technical Analysis for MLTX - MoonLake Immunotherapeutics
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -0.93% | |
| Fell Below 20 DMA | Bearish | -1.02% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -1.02% | |
| NR7 | Range Contraction | -1.02% | |
| Inside Day | Range Contraction | -1.02% | |
| Gapped Down | Weakness | -1.02% |
| Alert | Time |
|---|---|
| Outside Day | 1 day ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 1% | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/05/2024
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 64.98 |
| 52 Week Low | 24.31 |
| Average Volume | 363,182 |
| 200-Day Moving Average | 51.04 |
| 50-Day Moving Average | 43.81 |
| 20-Day Moving Average | 41.28 |
| 10-Day Moving Average | 40.26 |
| Average True Range | 1.93 |
| RSI (14) | 44.13 |
| ADX | 19.93 |
| +DI | 19.88 |
| -DI | 20.04 |
| Chandelier Exit (Long, 3 ATRs) | 39.77 |
| Chandelier Exit (Short, 3 ATRs) | 43.62 |
| Upper Bollinger Bands | 44.57 |
| Lower Bollinger Band | 37.99 |
| Percent B (%b) | 0.41 |
| BandWidth | 15.94 |
| MACD Line | -0.84 |
| MACD Signal Line | -1.10 |
| MACD Histogram | 0.2569 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 43.74 | ||||
| Resistance 3 (R3) | 43.98 | 43.19 | 43.22 | ||
| Resistance 2 (R2) | 43.19 | 42.41 | 43.07 | 43.05 | |
| Resistance 1 (R1) | 41.93 | 41.93 | 41.54 | 41.69 | 42.88 |
| Pivot Point | 41.14 | 41.14 | 40.95 | 41.02 | 41.14 |
| Support 1 (S1) | 39.88 | 40.36 | 39.49 | 39.64 | 38.44 |
| Support 2 (S2) | 39.09 | 39.88 | 38.97 | 38.27 | |
| Support 3 (S3) | 37.83 | 39.09 | 38.10 | ||
| Support 4 (S4) | 37.59 |
